Glatiramer Acetate
- Generic Name
- Glatiramer Acetate
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗复发型多发性硬化症（MS/罕见病），包括成人临床孤立综合征、复发-缓解性疾病和活动性继发进行性疾病。
- Associated Conditions
- -
- Associated Therapies
- -
Where Are They Now Teva Pharmaceuticals
Teva's strategy evolved from focusing on high-value generics and new drugs under Jeremy Levin to a pivot to growth strategy under Richard Francis, emphasizing biosimilars. Teva currently markets three biosimilars in the U.S. and plans to launch Selarsdi in 2025. Revenue growth is driven by branded portfolio, including Austedo XR, expected to bring in $1.6 billion in 2024.
A Rising EU Antitrust Enforcement Tide: 'Exclusionary Disparagement' of Pharma Rivals
The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.
Teva Fined €463M for Blocking Rival MS Drug Launch, EU Says
EU fined Teva Pharmaceutical Industries €463 million for spreading misleading info about Synthon's MS drug, delaying competition and driving up costs. Prices dropped 80% after Synthon's entry.
Teva fined $503 million by EU for disparaging rival product
Teva fined 462.6 million euros by EU for abusing dominant position to delay competition to MS drug Copaxone; Teva plans to appeal.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath